Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline
MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates on its clinical pipeline, including completion of enrollment for a Phase 3 …
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline Read More